Neuraxpharm Strengthens Commitment to Multiple Sclerosis at ECTRIMS 2025 in Barcelona

Neuraxpharm Showcases Commitment to Multiple Sclerosis at ECTRIMS 2025

Neuraxpharm Group, a prominent player in the European pharmaceutical industry, is set to make its mark at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), happening from September 24 to 26, 2025, in Barcelona, Spain. This annual congress is a crucial event for the latest advancements in the treatment and understanding of multiple sclerosis (MS), bringing together researchers, healthcare professionals, and industry leaders from around the globe.

Collaborative Engagement at ECTRIMS

With its strategic partner,TG Therapeutics, Neuraxpharm will present an engaging experience at their dedicated booth, encapsulating the essence of their collaboration in advancing MS therapies. Attendees will have the opportunity to hear from recognized experts during exclusive interactive Boothtalks, focusing on the evolving therapeutic landscape for MS and disseminating valuable clinical insights.

Moreover, both companies will share important data concerning patients with relapsing forms of multiple sclerosis (RRMS) throughout various sessions tailored toward healthcare professionals and researchers. These presentations will draw from both clinical trial results and real-world evidence, underscoring the importance of this knowledge in refining treatment strategies.

Commitment to Advancing MS Care

Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, stated, “Our participation in ECTRIMS embodies our unwavering commitment to enhancing the quality of care for individuals living with multiple sclerosis. We aim to broaden the accessibility of innovative therapies and provide distinct products that cater to the needs of patients and healthcare providers across Europe and beyond.” This sentiment resonates with Neuraxpharm's growth strategy, which hinges on delivering cutting-edge CNS solutions while maintaining a strong foothold as a specialist in the field.

Neuraxpharm's production facility in Sant Joan Despí, Barcelona, stands as a testament to its commitment to innovation and efficacy in pharmaceutical development. The site not only serves as a manufacturing hub for their own products but also partners with national and international entities to deliver high-quality solutions. As part of their burgeoning research and development capabilities, they proudly house a HealthTech R&D Center dedicated to fostering innovation with over 25 new products currently in the pipeline, reinforcing their position in the CNS disorder market.

Global Reach and Impact

Contrary to its impressive advancements, Neuraxpharm hasn’t limited its growth to the European landscape alone; it has dynamically expanded its operations to encompass over 20 countries in Europe and has recently ventured into markets in Latin America, the Middle East, and Australia. Their wide-reaching network, which touches 98% of the European CNS market, exemplifies their dedication to improving the quality of life for countless patients in more than 50 countries.

With a workforce exceeding 500 in Spain—including personnel at their manufacturing plant and R&D center—Neuraxpharm embodies a robust commitment to its mission. On a larger scale, the organization boasts around 1,000 global employees, each contributing to the advancements and breakthroughs within the CNS arena.

The collaboration with TG Therapeutics at ECTRIMS symbolizes not just a partnership but a shared vision to revolutionize the treatment landscape for multiple sclerosis. As Neuraxpharm continues its innovative journey, it remains resolutely focused on addressing unmet medical needs across neurology, psychiatry, and particularly multiple sclerosis.

About Neuraxpharm Group

Neuraxpharm is recognized for its expertise in addressing CNS disorders, with a rich legacy of 40 years in the field. The firm dedicates itself to constant innovation, developing new solutions that effectively meet patient requirements through a balance of internal R&D, partnerships, and strategic acquisitions.

For more details about Neuraxpharm's initiatives and their mission, visit their official website: Neuraxpharm.

Acknowledging ECTRIMS

The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) stands as a leading institution globally, dedicated to the improvements in MS treatment and understanding. The 41st Congress is anticipated to be a pivotal event, fueling collaboration and fostering new ideas among the world’s top professionals in the field.

In conclusion, Neuraxpharm's proactive involvement in ECTRIMS underscores its commitment to leading within the CNS therapeutic space, reinforcing its reputation as a key driver of innovation and patient-focused care.